FDA accepts Roche’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer

26 October 2017 FDA accepts Roche’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) in combination with chemotherapy (carboplatin... Read more

Shimadzu Donates Mass Spectrometer to the International Atomic Energy Agency Supporting developing nations by applying nuclear technology to food safety

Shimadzu Corporation and the IAEA (International Atomic Energy Agency, headquartered in Vienna, Austria)*1 have agreed on the donation of a Shimadzu LCMS-8060 High-Performance Liquid Chromatograph Mass Spectrometer*2 to the agency. IAEA Director General Yukiya Amano and Shimadzu Corporation Chairman Akira Nakamoto attended the signing ceremony for the Memorandum of Cooperation at Shimadzu Corporation Head Office... Read more

Shimadzu Donates Mass Spectrometer to the International Atomic Energy Agency Supporting developing nations by applying nuclear technology to food safety

Shimadzu Corporation and the IAEA (International Atomic Energy Agency, headquartered in Vienna, Austria)*1 have agreed on the donation of a Shimadzu LCMS-8060 High-Performance Liquid Chromatograph Mass Spectrometer*2 to the agency. IAEA Director General Yukiya Amano and Shimadzu Corporation Chairman Akira Nakamoto attended the signing ceremony for the Memorandum of Cooperation at Shimadzu Corporation Head Office... Read more

Eppendorf India expands the training facility in Chennai

October 2017 Eppendorf India announces the extension of the training centre at its facility in Ambattur. Eppendorf India, a wholly owned subsidiary of Eppendorf AG, today announces the extension of the training centre at its facility in Ambattur, Chennai. Eppendorf is committed to skill development and this measure further enhances the possibility of offering tailor... Read more

VWR and Scientist.com Collaborate to Create an End-to-End Online Research Solution

RADNOR, Pa., Oct. 17, 2017 /PRNewswire/ — VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, today announced its collaborating with Scientist.com, the leading global online marketplace for research services. VWR customers in the U.S. can now purchase thousands of custom products and research services through... Read more

FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus

Basel, 06 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses and newborn infants cobas Zika complements efforts to prevent the spread of Zika virus through blood donations in the U.S. cobas Zika... Read more

FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus

Basel, 06 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses and newborn infants cobas Zika complements efforts to prevent the spread of Zika virus through blood donations in the U.S. cobas Zika... Read more

Mining and Soil Modes Added to Smallest and Lightest Handheld XRF Elemental Analyzer

Mining and Soil Modes Added to Smallest and Lightest Handheld XRF Elemental Analyzer Thermo Scientific Niton XL5 handheld XRF analyzer now offers additional functionality and new accessories, including collapsible mini test stand TEWKSBURY, Mass., Oct. 2, 2017 /PRNewswire/ — Geologists, mining companies and environmental laboratories can now generate x-ray fluorescence (XRF) analysis faster in the... Read more

FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer

Basel, 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin®... Read more

FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer

Basel, 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin®... Read more